聯泓新科(003022.SZ):已完成增資江西科院生物新材料
格隆匯6月23日丨聯泓新科(003022.SZ)公佈,此前披露,基於公司發展戰略,為佈局生物可降解材料領域,公司第一屆董事會第十八次會議、第一屆監事會第十二次會議分別審議通過了《關於增資江西科院生物新材料有限公司暨關聯交易的議案》,同意公司對江西科院生物新材料有限公司(“標的公司”)增資人民幣1.5億元。此次增資完成後,標的公司將成為公司持股42.86%的聯營企業。
截至公吿披露日,公司已完成上述增資事項,標的公司已辦理完畢相關工商變更登記手續,註冊資本變更為20650萬元整,並取得了變更後的營業執照。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.